Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
1(10%)
Results Posted
57%(4 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_1
6
60%
Ph phase_2
4
40%

Phase Distribution

6

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
6(60.0%)
Phase 2Efficacy & side effects
4(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(7)
Terminated(2)

Detailed Status

Completed7
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
77.8%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (60.0%)
Phase 24 (40.0%)

Trials by Status

completed770%
active_not_recruiting110%
terminated220%

Recent Activity

1 active trials
Showing 5 of 10
active_not_recruitingphase_1

Phase I Comparative Bioavailability Study

NCT00777582
completedphase_2

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

NCT00753545
completedphase_1

Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients

NCT00782574
completedphase_2

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

NCT00679783
terminatedphase_2

OLAParib COmbinations

NCT02576444
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00777582Phase 1

Phase I Comparative Bioavailability Study

Active Not Recruiting
NCT00753545Phase 2

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Completed
NCT00782574Phase 1

Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients

Completed
NCT00679783Phase 2

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

Completed
NCT02576444Phase 2

OLAParib COmbinations

Terminated
NCT00819221Phase 1

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

Terminated
NCT00628251Phase 2

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

Completed
NCT00707707Phase 1

Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

Completed
NCT00710268Phase 1

Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours

Completed
NCT00633269Phase 1

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10